Responses
Immunotherapy biomarkers
Original research
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.